About Event
This two-day conference focuses on translational aspects of substance use research among chemists, biologists, and behavioral scientists. The diversity of participants and attendees at this meeting (undergraduate students to senior faculty, chemists to psychiatrists) provides a unique venue for networking among different disciplines and in so doing promotes new and innovative approaches to medications development in addictions biology. The meeting provides a stimulating environment for young scientists who are strongly encouraged to present their work and interact with senior scientists. The BBC meeting has served as a “launch pad” for many young, innovative investigators to join the ever-growing world of SUD research.
Abstract Submission Information |
||
|
Abstracts must describe the results of original, unpublished research that involves collecting and analyzing data. Abstracts must include the following: rationale, hypothesis, species, number of subjects, procedures (methods and statistical analyses), results, and conclusions (importance of findings). Abstracts are submitted with the travel award application, or at the time of registration. |
||
Abstract Deadline: 24 February 2023 Download Abstract Submission Form | ||
| --> | Registration Fees
$150 | Presenting Students and Postdocs (waived for travel awardees) |
Event Speakers
.jpg) |
Bill Stoops, PhDUniversity of Kentucky College of Medicine |
||
 |
Carrie Jones, PhDChief, Molecular Neuropsychiatry Research Branch, Vanderbilt University |
Modeling methamphetamine addiction in rodents: epigenetic consequences |
Lunch & Learn!
 |
Yu (Woody) Lin, MD, PhDDivision of Neuroscience and Behavior, NIDA |
Strategies to succeed research career transition and independence |
Plenary Symposium
 |
Paule Joseph, PhDNational Institute of Alcohol Abuse and Alcoholism, NIH |
Inflammatory markers of substance use and mood disorders |
|
 |
Irma (Lisa) Cisneros, PhDUniversity of Texas Medical Branch |
Danger-associated molecular patterns (DAMPS) and mitochondrial antiviral protein (MAVS) trigger neuroinflammatory networks in substance use disorder
|
|
 |
Saadet Inan, MD, PhDTemple University |
Chemokine and cytokine receptor antagonists as potential therapeutics for psychostimulant use disorder |
|
 |
Marisa Roberto, PhDScripps Research Institute |
Neuroimmune systems as therapeutic targets for mental health and substance use disorders |